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ABSTRACT 
Gammadelta T (γδT) lymphocytes have provoked interest in oncology, particularly as 
regards their potential use in immunotherapy, because of their unique ability to recognise 
antigens without a requirement for major histocompatibility complex antigen presentation, 
and to quickly activate an anti-tumour response. However, work in some cancers has 
suggested that they also have pro-tumourigenic activity. Their role in breast cancer is 
unclear. This review outlines the evidence to date in in vitro studies, in vivo mouse models 
and in human studies regarding the role of γδT lymphocytes in breast cancer. We describe 
the seemingly opposing roles of the predominantly circulating Vγ9Vδ2+ subtype, which can 
suppress tumour growth through direct cytotoxicity, induction of apoptosis and inhibition of 
angiogenesis, and the predominantly tumour-infiltrating γδ1+ subtype which can promote 
tumour growth and spread through immunosuppressant effects. We summarise the 
evidence in breast cancer for the mechanisms of action of γδT lymphocytes and describe 
how factors in the tumour microenvironment may affect their function, polarising them 
towards a pro-tumourigenic, immune-suppressing role.  We also describe the experience to 
date of γδT lymphocytes in immunotherapy for breast cancer and suggest the direction of 
work going forward, particularly as regards different breast cancer subtypes. 
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INTRODUCTION 
 Breast cancer is the most common cancer in females, and the second most common 
cause of cancer death in females in the UK.   Despite significant advances in treatment over 
the last two decades, breast cancer still accounted for 11,433 deaths in the UK in 2014(1). 
Therefore, work is ongoing to develop more effective, targeted treatments, as well as 
reliable prognostic markers to help guide treatment regimen. 
 It is increasingly being recognised that the tumour microenvironment has an 
important role to play in the progression and dissemination of cancer(2, 3). The components 
of the tumour microenvironment, including fibroblasts, tumour-associated stroma and 
various immune cells, have different roles to play in the promotion or suppression of 
tumour growth. One small component of this microenvironment in humans is gamma delta 
T (γδT) lymphocytes, which are members of the immune system which display both innate 
and adaptive functions which vary between subtypes(4-6). Evidence of their cytotoxic 
activity against tumour cells in certain cancers, particularly cutaneous malignancy(7), as well 
as their ability to recognise tumour cells without the need for major histocompatibility 
complex (MHC) antigen presentation, has suggested that they may have a promising role in 
immunotherapy. However, more recent evidence in colorectal, ovarian and breast cancer 
has suggested that γδT lymphocytes may also have a pro-tumourigenic role(8-10). Several 
reviews over the last few years have described the role of γδT lymphocytes in cancer in 
general(11-15), but this review will summarise the evidence to date regarding γδT 
lymphocytes in breast cancer. 
THE IMMUNE FUNCTION OF γδT LYMPHOCYTES 
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 γδT lymphocytes, identified in the mid-1980s(16, 17), make up 0.5-16% (average of 
4%) of CD3+ cells in the blood and organised lymphoid tissues, and 10-30% in the intestine 
of healthy adult human subjects.(18). There are many different subtypes of γδT 
lymphocytes, with distinct phenotypic and functional properties, with some displaying more 
innate features and others more adaptive features(5). In humans, for example, Vδ1+ T 
lymphocytes are the predominant subtype found in intestinal (along with Vδ3) and skin 
tissues while Vδ2+ T lymphocytes make up the majority of those found in peripheral 
blood(18). Within these broad subtypes there are further specific subtypes. For example, a 
subset of Vδ1 and Vδ3 T lymphocytes found in the liver are distinct from those found in 
blood(19), and Vδ2+ lymphocytes can be divided in to innate-like Vγ9+Vδ2+ and adaptive Vγ9-
Vδ2+subsets (5). 
γδT lymphocytes are characterised by T cell receptors (TCR) made up of γ and δ 
chains. In contrast to αβT lymphocytes, most do not display CD4 or CD8 co-receptors. 
Therefore, antigen recognition is not restricted to MHC molecules(18). They also express 
natural killer receptors (e.g. NKG2D) and thus, are sometimes considered to represent a link 
between the innate and adaptive immune systems(20). γδTCR recognise a diverse array of 
antigens including peptides, unprocessed proteins, sulfatides and phospholipids(17, 18). 
Furthermore, phosphoantigens have been identified as potent γδT lymphocyte 
stimulators(21). These pyrophosphate molecules are intermediates of the eukaryotic 
mevalonate, and the prokaryotic non-mevalonate pathways for isoprenoid synthesis. 
Examples include (E)-4-hydroxy-3-methyl-but-2-enylpyrophosphate (HMBPP), which is 
produced by microbes, and isopentyl pyrophosphate (IPP) which is overproduced by 
transformed eukaryotic cells. Recognition of these molecules by γδT lymphocytes is 
therefore key to their role in both anti-microbial and anti-tumour immunity(16).  As γδT 
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lymphocyte activation is not reliant on antigen processing, it has been suggested that they 
can rapidly activate an immune response(18). However, there is some evidence in the 
context of cytomegalovirus and malaria infections, that γδT lymphocytes may be activated 
later in the immune response(22, 23). This response can be both in the form of direct 
cytotoxicity (through the perforin-granzyme pathway), and via stimulatory and regulatory 
effects on other components of the immune system, through secretion of cytokines such as 
IFNγ and TNFα, or by direct antigen presentation(21). 
TECHNIQUES FOR THE ISOLATION AND EXPANSION OF γδT LYMPHOCYTES 
The ability to isolate and expand γδT lymphocytes from human blood or tumour 
tissues facilitates further investigation of their actions. Examples of methods by which this 
can be achieved are as follows. Peripheral blood mononuclear cells are isolated from blood 
by centrifugation, then the cells are stimulated and cultured along with Il-2. αβT 
lymphocytes and CD4+ T lymphocytes can be removed using specific antibodies and 
magnetic bead selection, then the γδT lymphocytes are cloned(24). To obtain lymphocytes 
from tumour tissue the tissue is first minced and digested by enzymes to release the 
lymphocytes prior to culture and cloning(25). The DOT method, described by Almeida et al 
in a chronic lymphocytic leukaemia model, uses a two-step method whereby isolated γδT 
lymphocytes are cultured with anti-CD3 mAB, IL-4 and IFNγ followed by a second period of 
culture using IL-15 in place of IL-4. This resulted in selective expansion of cytotoxic Vδ1+ T 
lymphocytes(26). Furthermore, a method which isolates T lymphocytes by encouraging their 
migration out of epithelial tissues has been described to obtain T lymphocytes from skin(27) 
and then modified for use in gut(28). Briefly, samples of skin or gut are cultured on matrices 
with IL-2 and IL-15 added to the medium, during which time the lymphocytes migrate out of 
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the tissue and can be harvested. It should be cautioned that the method used my affect 
what subtype is preferentially expanded. 
 γδT LYMPHOCYTES IN BREAST CANCER - IN VITRO AND MURINE STUDIES 
In vitro studies of peripherally-derived γδT lymphocytes 
 Early in vitro studies demonstrated anti-tumourigenic activity of γδT lymphocytes in 
breast cancer cell lines. Bank et al first described the cytotoxicity of Vγ9Vδ2+ T cells, derived 
from normal peripheral blood, against the MCF7 breast carcinoma cell line(29). Similarly, 
Guo and co-workers used ex-vivo expanded γδT lymphocytes from healthy donors and 
showed Vδ2 lymphocytes to be cytolytic against several breast cell lines (the luminal A MCF-
7 and T-47D lines, and the triple negative MDA-MB-231 line). Importantly, they also 
observed that they recognised and exhibited lytic activity against human breast cancer cells 
but not non-malignant cells. There was also a 75% reduction in lysis when co-cultured with a 
TCR antibody suggesting that their cytotoxicity is TCR-dependent(30). A caveat to this was 
however reported in 2017, that the antibodies to the TCR used in such studies may actually 
be inducing apoptosis of the γδT lymphocytes resulting in reduced cytotoxicity, rather than 
blockage of the TCR (31). A further study observed similar findings in that in vitro mouse-
derived γδT lymphocytes were cytotoxic to tumour cells (the triple-negative 4T1 mammary 
adenocarcinoma cell line), but not the non-malignant fibroblasts(32). However, it is 
important to note that this latter study used mouse-derived γδT lymphocytes which 
represent a different subset to those found in humans, which may behave differently.  
 Later, more detailed work in different subtypes of breast cancer was carried out. 
Aggarwal and co-workers demonstrated dose-dependent inhibition of cell survivability and 
proliferation when tumour cells were co-cultured with human peripheral blood expanded 
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γδT lymphocytes. This was observed in all breast cancer cell lines used (MCF-7, HER2+ 
SkBr7, ER- MDA-MB-231), except for the BrCa-MZ01 cell line (ER/PR+), which conversely, 
showed increased proliferation with γδT lymphocytes. On further investigation, it was found 
that MICA/B (previously reported to engage with NKG2D receptor) was expressed on the 
sensitive cell lines but not the resistant one. Furthermore, although intercellular adhesion 
molecule 1 (ICAM1) was expressed on all cell lines, it was found to be up regulated in the 
sensitive cell lines and down regulated in the resistant cell line, suggesting that these 
molecules play a role in γδT lymphocyte cytotoxicity(33). A role for ICAM1 in tumour cell 
recognition is supported by evidence, in other cancer types, that it is a costimulatory ligand 
in endothelial protein C receptor-dependent recognition of tumour cell lines (HT29 colon 
cancer, K562 chronic myelogenous leukaemia and U937 lymphoma) by Vδ2- γδT 
lymphocytes(34).  
The authors of the Aggarwal study suggest that γδT lymphocytes inhibit angiogenic 
signalling pathways and increase apoptosis. They noted that signalling pathways associated 
with cell survival, AKT and ERK, had reduced phosphorylation in the sensitive cell lines but 
this was up regulated in the resistant cell line. Furthermore, activation of pro-apoptotic 
signals such as PARP and cleaved Capsase 3 was significantly up regulated in sensitive cell 
lines suggesting that γδT lymphocytes induce apoptotic stress(33). 
In vivo studies of peripherally-derived γδT lymphocytes 
Some of the studies described above went on to further investigate their in vitro 
findings in murine models. Beck and co-workers found that their mouse-derived γδT 
lymphocytes localised to the tumour in vivo as long as the γδTCR was unblocked, providing 
additional evidence that this is a critical mode of tumour cell recognition(32) 
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In the Aggarwal et al study, when mice were injected in vivo with human-derived γδT 
lymphocytes and either the SkBr7 or the BrCa-MZ01 cancer cell line, tumour growth was 
reduced compared with those injected with the breast cancer cell line alone. This is 
particularly interesting in the case of the latter cell line, in view of the in vitro results 
detailed above, and the reasons for this variation in response were unclear. Similarly to the 
in vitro results, AKT, ERK and STAT3 phosphorylation were down regulated in the tumours of 
mice that were co-injected with γδT lymphocytes, compared to those injected with a cancer 
cell line only. Higher numbers of apoptotic cells were seen in these tumours and there were 
higher levels of cleaved Capsase 3. These tumours also showed down regulation of VEGF 
and ENOS when mice were injected with both tumour cells and γδT lymphocytes, as well as 
reduced angiogenesis(33). 
In an earlier study, Beck et al had similarly reported that, in a syngeneic mouse 
model, when tumour-bearing mice injected with the 4T1 cell line were treated with ex vivo 
expanded murine γδT lymphocytes, a significant reduction in tumour growth was observed 
compared to untreated controls. Similar results were observed when human γδT 
lymphocytes were applied to a human xenograft model of breast cancer (using the 2LMP 
human breast cancer cell line) in the mice(32).  
In vitro studies of tumour-infiltrating γδT lymphocytes 
 The studies above used γδT lymphocytes from blood which, as previously 
mentioned, in humans are predominantly of the Vγ9Vδ2+ subtype. On the other hand, the 
γδT lymphocyte population of breast tumour-derived tumour infiltrating lymphocytes (TILs) 
have been shown to be predominantly (95%) of the Vδ1+ subtype, which make up 7.2-75.7% 
of breast tumour-derived TILs(25). In 2007, Peng et al showed that, in vitro, breast tumour-
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derived TILs had an immune-suppressive role. They suppressed naïve T cell proliferation, as 
well as Il-2 production by CD4 and CD8 cells, and blocked dendritic cell (DC) maturation and 
cytokine secretion (25).  
 Since then, further work has attempted to elucidate the mechanisms by which γδT 
lymphocytes may promote tumour progression in breast cancer.  Ye et al assessed the effect 
of human tumour-derived γδT lymphocytes on other immune cells in vitro. These γδT 
lymphocytes were functionally γδT regulatory (Treg) lymphocytes, which induced cell cycle 
arrest in cytotoxic T lymphocytes. Along with CD4 Tregs, they suppressed naïve T cell 
proliferation through induction of T cell senescence. It was observed that senescent CD4+ 
and CD8+ lymphocytes secreted large amounts of proinflammatory IL-6, IFNγ and TNFα, but 
also IL-10 and modified TGFβ1, suggesting a negative regulatory function. These senescent T 
lymphocytes also inhibited proliferation of functioning CD4+ T- lymphocytes.  Furthermore, 
γδTreg lymphocytes inhibited proliferation of Th1 and Th17 effectors. Additionally, they 
induced senescence in DCs, which had a distinct deficiency in their maturation and co-
stimulatory function, and lost their capacity to process and present antigens. Through 
investigation of ways to overcome this induction of T cell and DC senescence by γδT 
lymphocytes, the group demonstrated that toll-like receptor 8 (TLR8) signalling can prevent 
γδTreg-mediated senescence induction in functioning T- lymphocytes and DCs(35).  
In vivo studies of tumour-infiltrating γδT lymphocytes 
Both groups then tested their finding using in vivo mouse models. The Peng group 
confirmed the immune-suppressive role of breast tumour derived TILs observing that they 
suppressed the ability of CD8+ cells to kill tumour cells(25). Ye et al confirmed that γδTreg 
lymphocytes induced functioning T cell senescence, which in turn suppressed the 
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proliferation of functioning CD4+ lymphocytes. Furthermore they confirmed that 
manipulation of TLR8 signalling could prevent this senescence(35). 
Investigation of IL-17 –secreting γδT lymphocytes 
 A 2015 study by Coffelt et al primarily investigated the role of neutrophils in breast 
tumour metastasis formation in mice. However, as a result of their investigations they 
demonstrated a requirement for the IL-17 - GCSF signalling cascade for neutrophil 
expansion. This was particularly required for the CD8-suppressing neutrophil phenotype to 
predominate, and drive metastases. When investigating the source of the IL-17, they found 
that splenic-derived γδT and CD4+ T lymphocytes both expressed IL-17A. However, only γδT 
lymphocyte depletion led to reduced IL17A and GCSF serum levels, reduced circulating 
neutrophils and a reversal of the CD8-suppressing neutrophil phenotype. Furthermore, 
depletion of γδT lymphocytes in the early phase of tumourigenesis in this mouse model 
reduced pulmonary and lymph node metastases but not primary tumour growth(36).  
Other studies have also suggested that γδT lymphocytes serve as an important 
source of IL-17, which in addition to the mechanism described above, can also promote 
tumour growth by suppression of tumour cell apoptosis and by induction of angiogenic 
factors(37). However, while IL-17- secreting γδT lymphocytes are common in mice, they are 
extremely rare, particularly in health, in humans(38). Because of this, most studies of γδT17 
lymphocytes have been carried out in mice rather than humans, and it is currently not clear 
how similar the murine and human subsets are, and therefore how far findings in mouse 
studies can be applied to humans(38). In humans there is evidence that a highly 
inflammatory milieu is required for polarisation to an IL-17-secreting phenotype(15). IL-17 
has been shown to be associated with more aggressive tumours and worse outcomes in 
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breast cancer, but it can be produced by a number of immune cells other than γδT 
lymphocytes, including Th17 lymphocytes and macrophages(37). Therefore, it is currently 
uncertain how significant the role of IL-17 -secreting γδT lymphocytes is in human breast 
cancer.   
 In summary, both in vitro and in vivo studies demonstrate that different subtypes of 
γδT lymphocytes have seemingly opposing effects on the growth of breast tumours. 
Vγ9Vδ2+ T lymphocytes, the subtype found in peripheral blood, display cytotoxicity towards 
breast tumour cells, increase apoptosis and inhibit angiogenic signalling pathways. These 
actions may be breast cancer subtype dependent, rely on specific signalling pathways, be 
TCR-dependent, and change depending on MICA/B and ICAM1 expression levels. 
Conversely, Vδ1+ T lymphocytes, the predominant subtype found in breast tumours, 
demonstrate pro-tumour activity through a number of immune-suppressing effects. These 
include suppression of naïve T cell proliferation and DC maturation via induction of 
senescence, which in turn inhibits proliferation of functioning T lymphocytes and DCs, which 
lose their capacity to process and present antigens. Furthermore, Vδ1+ T lymphocytes also 
secrete immunosuppressant cytokines.  
γδT LYMPHOCYTES IN BREAST CANCER - HUMAN STUDIES 
 There is a comparative paucity of translational studies in humans utilising tissue or 
blood samples. A 2009 study took blood samples from 38 patients with a new diagnosis of 
breast cancer and compared them to blood samples from 79 age-matched healthy controls. 
They found the proportion of γδT lymphocytes in the circulating blood of healthy controls to 
be 1.6 times higher than that in the breast cancer patients (p=0.002)(39). As an extension to 
this, later studies have observed that higher T stage (a measure of the extent of the tumour) 
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is correlated with lower circulating Vγ9Vδ2+ T lymphocytes in breast cancer patients(40). In 
the 2009 study, expanded γδT lymphocytes from breast cancer patients produced 
significantly higher quantities of IL-6 and TNFα but less IFNγ (p<0.05) than those from 
healthy subjects, and had a higher percentage of effector CD27- cells than CD27+ memory 
cells. The authors also noted that the γδT lymphocytes from the cancer patients released 
significantly less granzyme B, which is one mechanism by which γδT lymphocytes exert their 
cytotoxicity, than those from healthy donors (p<0.02). While there was generally higher 
cytotoxicity from the cells of healthy controls, this did not reach statistical significance(39). 
The reduced levels of circulating γδT lymphocytes in patients with tumours compared to 
healthy individuals, and with increasing stage, seen in these translational studies may 
provide some support to the in vitro and in vivo observations of the localisation of these 
cells to tumour, as described earlier. Alternatively, this observation may represent an effect 
of the tumour on γδT lymphocytes as it progresses, reducing their anti-tumoural efficacy. 
Alternatively, patients with low circulating γδT lymphocytes may be more susceptible to 
breast cancer. 
In contrast, previously described experimental studies by Peng et al and Ye et al 
suggested that γδT lymphocytes in the tumour microenvironment promoted tumour 
growth(25, 35).  These results were supported by Ma et al who compared tumour tissue 
from 81 patients to paired normal tissue. They found that numbers of γδT lymphocytes in 
the tissue positively correlated with higher T stage, positive lymph node status and HER2 
expression. Patients with higher numbers of γδT lymphocytes in tumour tissue had worse 
recurrence free survival (HR 34.68; 95% CI: 4.79-250.88; p=0.0004) and worse overall 
survival (HR 3.34; 95% CI: 1.21-9.25; p=0.002). Furthermore, these findings were not 
subtype specific(10). 
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Similarly, Ye et al, in a cohort of 46 patients, found significantly increased numbers of 
Vδ1+ T lymphocytes in fresh breast tumour tissues compared to paired normal tissue, with 
higher expression in late stage tissues compared to earlier stages. They then investigated 
reasons for this finding in vitro, and found that supernatants from breast cancer tissues and 
cell lines induced significant migration of Vδ1+ T lymphocytes. This effect was not seen for 
melanoma or colorectal cancers. Furthermore, no difference in chemotactic activity was 
observed between the different breast cancer subtypes. This activity seemed to be 
mediated via IP-10 secreted by the breast cancer cells, as a neutralising antibody to IP-10 
abolished the chemotaxis. In human breast tissue, Vδ1+ T lymphocytes surrounded IP-10 
expressing cancer cells. In a murine model, when human Vδ1+ T lymphocytes were injected, 
they accumulated at the tumour site within 3-10 days whereas γδ2+ and CD4+ T cells did 
not. The IP-10 antibody again inhibited chemotaxis and led to enhanced CD8-mediated anti-
tumour immunity(41).  
In a small study, which focussed on triple negative breast cancer, Hidalgo and co-
workers demonstrated that the lymphocytic infiltrate of these tumours contained many γδT 
lymphocytes, compared to normal breast tissue. They compared ductal and medullary 
breast cancer tissue and found differences in the distribution of γδT lymphocytes between 
the two tumour types; they were more frequently located in the stroma of the ductal 
specimens whereas they were more typically located in the tumour parenchyma and at the 
invasive tumour cell margin of medullary tumours(42). 
In contrast, a more recent study by Bense et al seems to suggest a more favourable 
role for γδT lymphocytes in breast cancer, in patients treated with chemotherapy. Their 
initial dataset analysed gene expression profiles of tumours from 7270 newly diagnosed 
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non-metastatic breast cancer patients (prior to any treatment) by performing in-silico 
analyses.  They used CIBERSORT (a method for characterising the cell composition of tissues 
from their gene expression profiles(43)) to estimate the fractions of 22 immune cell types. In 
611 patients who underwent neoadjuvant therapy, they found that a higher fraction of γδT 
lymphocytes was associated with a higher pathological complete response (pCR) rate (OR 
1.55; 95% CI:1.01-2.38; p=0.046). In 846 patients who received either neoadjuvant or 
adjuvant chemotherapy they reported prolonged DFS (HR 0.68; 95% CI 0.48-0.98; p=0.040), 
independent of receptor status, and improved overall survival in the HER2 positive subtype 
(HR 0.27; 95% CI:0.10-0.73; p=0.009). It should be noted that a significant proportion (75.7-
88.5%) of the immunohistochemistry-derived receptor status were not given in pathology 
data so these were inferred using mRNA expression. Therefore, the subtype-specific results 
of this study are not directly comparable to the others included in this review(44). In 
addition, it should be cautioned that there is some evidence of potential overlap of gene 
signatures using CIBERSORT between γδT lymphocytes and other immune cells such as CD4, 
CD8 and natural killer cells(45). 
These few studies, in correlation with the in vitro and murine studies of Vδ1+ T 
lymphocytes, suggest that tumours may actively recruit this subtype of γδT lymphocyte that 
correlates with higher disease stage and worse prognosis, adding supporting evidence to 
their pro-tumourigenic activity.  This is in contrast to the Vγ9Vδ2+ subtype, which decreases 
in number and shows reduced anti-tumour effectiveness as tumour stage increases, 
suggesting that the tumour may act to reduce the numbers and effectiveness of this 
subtype in the circulation. It should be noted however that these studies were carried out in 
small cohorts and therefore larger studies are required to validate these results. 
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Work both in breast cancer and in a variety of other cancers, however, tells us that 
the situation is not as ‘black and white’ as there being simply a pro-tumour Vδ1+ subtype 
and an anti-tumour Vγ9Vδ2+ T cell subtype. As Zhao et al comprehensively describe in their 
recent review, γδT lymphocytes display a degree of functional plasticity. Regardless of the 
configuration of their γδ chains, functionally they can be polarised to different subtypes, 
whether that be cytotoxic cells, γδTh lymphocytes, or FOXP3+ Treg lymphocytes, depending 
on the stimulus of various cytokines. It seems that the constituents of the tumour 
microenvironment may polarise γδT lymphocytes towards more pro-tumourigenic 
functional subtypes(15). 
With this in mind, the challenge being tackled by various groups is how to apply the 
characteristics of γδT lymphocytes in the clinical setting, in particular how to exploit their 
anti-tumourigenic effects without promoting their immune-suppressant characteristics. 
THERAPEUTIC APPLICATIONS OF γδT LYMPHOCYTES 
 There has been increasing interest in the use of bisphosphonates in breast cancer 
treatment.  A 2011 review summarises the clinical evidence for improved outcomes of 
patients treated with bisphosphonates, such as zoledronate, in several cancers but 
particularly in breast cancer in the neoadjuvant, adjuvant and metastatic settings. This 
evidence seems to be most marked in ER positive disease(46). The mechanisms behind the 
efficacy of bisphosphonates are not fully understood but one aspect may include 
immunomodulation via activation of Vγ9Vδ2+ T lymphocytes.  
 Investigating the mechanism of action of bisphosphonates against breast tumours, 
Dhar and co-workers showed that lysis of MCF-7 tumour cells pre-treated with 
bisphosphonates is mediated by γδTCRs and is partially NKG2D-dependent. They also 
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observed that γδT lymphocytes appeared to crawl over the surface of untreated tumour 
cells but were unable to form stable conjugates and lyse cells, whilst the zoledronate-
treated cells were surrounded by γδT lymphocytes, forming tight conjugates, and they lysed 
the tumour cells in a matter of seconds (47). Another study which pre-treated tumour cells 
with risedronate demonstrated that IFNγ secreted by γδT lymphocytes activates ICAM1 in 
luminal (ER positive) breast cell lines, which then leads to tumour recognition by ICAM 
engagement and subsequent tumour growth reduction(48) 
As well as increasing their anti-tumour efficacy, bisphosphonates have been shown 
to stimulate Vγ9Vδ2+ T lymphocyte expansion in vitro. Benzaid et al demonstrated, in in 
vitro and in vivo murine models, that treatment with zoledronate led to intracellular 
accumulation of isopentyl pyrophosphate (IPP) and triphosphoric acid 1-adenosin-5’-yl ester 
3-(3-methylbut-3-enyl)ester (ApppI) in luminal breast cancer cell lines (uptake of 
zoledronate was reduced in basal cell lines) which led to increased proliferation and 
mobilisation of Vγ9Vδ2+ T lymphocytes, with increased cytotoxicity(49).  
Lending support to the theory that γδT lymphocytes are important to the efficacy of 
bisphosphonate treatment, as suggested by these in vitro studies, are the results of a phase 
1 trial of zoledronate. 10 metastatic breast cancer patients were administered zoledronate 
in combination with IL-2, and peripheral blood Vγ9Vδ2+ T lymphocyte numbers were 
measured at regular intervals. They found that three quarters of patients surviving past 12 
months showed robust Vγ9Vδ2+ T lymphocyte numbers whereas the 3 patients who died 
between months 3-11 did so after a decline in Vγ9Vδ2+ T lymphocytes (50). 
Sugie et al investigated the importance of the frequency of bisphosphonate 
administration in cancer therapy. They monitored the effect on Vγ9Vδ2+ T lymphocyte 
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numbers in the peripheral blood of breast cancer patients after four weekly zoledronate 
injections and found that cell numbers progressively declined after each dose. Therefore, 
they postulated that the frequency/dosage interval of bisphosphonate administration might 
account for some of the variability in treatment response seen in the major clinical trials. 
They suggested that less frequent zoledronate infusion might be better than intensive 
zoledronate therapy at promoting the Vγ9Vδ2+ T lymphocyte effects in early stage breast 
cancer patients(40). 
 The ability of bisphosphonates to stimulate Vγ9Vδ2+ T lymphocytes has also led to 
interest in using Vγ9Vδ2+ T lymphocytes themselves as immunotherapy, however, clinical 
trials in various cancers have shown lower response rates than hoped with an average 
response ratio of 21%(15). There are two methods to perform immunotherapy using these 
cells, either by stimulating the population of Vγ9Vδ2+ T lymphocytes to expand in vivo, 
similarly to the studies above, or by adoptive transfer where the patient’s own Vγ9Vδ2+ T 
lymphocytes are expanded ex vivo using bisphosphonate stimulation prior to treatment. 
Sugie et al investigated Vγ9Vδ2+ T lymphocyte proliferation using the second 
method, ex vivo expansion. They observed that Vγ9Vδ2+ T lymphocyte proliferation in the 
presence of zoledronate and IL-2, as well as production of IFNγ and TNFα, was correlated to 
the initial Vγ9Vδ2+ T cell frequency in the patient’s blood. These observations suggest that 
immunotherapy may have limited effectiveness in patients with low circulating Vγ9Vδ2+ T 
lymphocyte levels. However, when they added IL-18 to zoledronate and IL-2, they found 
enhanced proliferative response and cytokine production, regardless of the initial Vγ9Vδ2+ T 
lymphocyte frequencies. They therefore concluded that, in this context, Vγ9Vδ2+ T cell 
immunotherapy is feasible for both early and late stage breast cancer(40).  
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The same group registered a phase II clinical trial in 2014 with the primary aim of 
assessing the add-on effect of a single dose of zoledronate with preoperative letrozole (a 
competitive inhibitor of the enzyme aromatase, used in the treatment of breast cancer to 
block the conversion of androgens to oestrogens in postmenopausal women) in cT1/2N0M0 
ER positive, Her2 negative breast cancer, but with the secondary aim of investigating the 
changes in frequency of Vγ9Vδ2+ T lymphocytes after the administration of zoledronate. It 
will also assess whether higher levels of peripheral Vγ9Vδ2 T lymphocytes pre-treatment are 
predictive of a better response(51).  
It has been suggested that bisphosphonates and Vγ9Vδ2+ T lymphocytes in 
combination may have clinical utility in metastatic bone disease in breast cancer, as the 
benefits of the actions of bisphosphonates on bone may be exploited in addition to the 
effects on γδT lymphocyte proliferation and function already described. A recent study 
demonstrated that, following pre-treatment of the mice with zoledronate, ex vivo expanded 
human Vγ9Vδ2+ T lymphocytes localised to the tumour in bone.  Furthermore, multiple 
infusions of Vγ9Vδ2+ T lymphocytes reduced bone tumour growth, and this effect was 
potentiated following zoledronate pre-treatment. These mice also had the lowest volume of 
pulmonary metastases and reduced osteolysis was also noted, suggesting a promising role 
for this combination therapy in bone metastases, permitting both reduction in bone 
degradation and reduction in tumour burden(52). 
 The use of γδT lymphocytes in combination with other agents has also been 
investigated.  One study showed that treatment of Her2 positive cell lines with γδT 
lymphocytes in combination with trastuzumab resulted in increased efficacy of the 
trastuzumab compared to trastuzumab or γδT lymphocytes alone. This also held true in 
20 
 
xenografts of this cell line in mice, showing reduced tumour growth in those treated with 
the combined therapy(53). 
 In addition to the therapeutic applications of γδT lymphocytes outlined above, some 
evidence summarised in this review, regarding correlations between numbers of γδTILs and 
cancer outcome measures, suggests a potential role for γδT lymphocytes as a predictive 
biomarker which could stratify patients for more aggressive systemic therapy. 
CONCLUSIONS 
In summary, γδT lymphocytes show unique potential in cancer immunotherapy due 
to their ability to recognise tumour cells independently of MHC antigen presentation and to 
rapidly initiate an immune response, bridging the innate and adaptive immune systems. 
They do this through direct cytotoxicity, secretion of cytokines such as TNFα and IFNγ that 
stimulate other components of the immune response, inhibition of angiogenesis, and 
through antigen presentation. However, functional plasticity where certain cytokines in the 
tumour microenvironment drive γδT lymphocytes towards an immunosuppressive role, has 
resulted in limitations to the effectiveness of immunotherapy to date. To elicit the full 
potential of this therapy, the goal of optimising the γδT lymphocyte subtype to an anti-
tumour role, and manipulating the tumour microenvironment to promote rather than 
inhibit this purpose must be pursued. Perhaps uniquely in breast cancer, early work has 
suggested that the effectiveness of γδT lymphocytes against tumours may vary in different 
molecular subtypes and therefore, work in breast cancer must be designed to fully evaluate 
effects within the different subtypes.  
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